Titan Biotech delivered impressive financial performance in the quarter ended June 2026, with consolidated net profit rising 58.31% to ₹10.86 crore compared to ₹6.86 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's strong operational performance during the quarter. The company also recognized approximately ₹1.40 crore as share of profit from an associate during Q1 FY27, compared with around ₹0.70 crore in the year-ago quarter and just ₹0.17 crore in Q4 FY26, providing an additional boost to consolidated net profit.
The company's sales revenue increased 27.25% to ₹59.17 crore in Q1 FY2026, up from ₹46.50 crore in the same quarter of the previous financial year. As reported by Business Standard, this revenue growth indicates strong demand for the company's products and services during the quarter. The company also recorded healthy sequential growth, with revenue rising around 21.2% from ₹48.83 crore in Q4 FY26. Other income stood at approximately ₹1.81 crore, compared with ₹0.72 crore in Q1 FY26 and ₹2.11 crore in the March quarter, with total income consequently standing at around ₹60.98 crore.
EBITDA increased 42.9% YoY to ₹12.49 crore compared with ₹8.74 crore in the previous year's corresponding quarter, with EBITDA margin expanding to 21.11% from 18.79% in Q1 FY26. According to Business Standard, this margin expansion of approximately 232 basis points year-on-year and around 123 basis points sequentially reflects better cost management and operational efficiency. Cost of materials consumed increased to approximately ₹29.93 crore, compared with ₹24.56 crore in Q1 FY26, while employee benefit expenses rose to ₹8.70 crore from ₹7.01 crore. Other expenses increased to approximately ₹10.09 crore from ₹6.80 crore, with total expenses standing at around ₹48.25 crore compared with ₹39.11 crore in Q1 FY26.
Profit Before Depreciation and Tax (PBDT) surged 52% to ₹14.10 crore from ₹9.26 crore in the previous year's corresponding quarter. As reported by Business Standard, Profit Before Tax (PBT) increased 57% to ₹12.73 crore from ₹8.11 crore in Q1 FY2025, indicating strong operational performance across all profitability metrics. Before including the share of profit from associates, PAT stood at approximately ₹9.46 crore, compared with ₹6.16 crore in Q1 FY26, with the company reporting no exceptional items in the quarter. The relatively low finance-cost burden of approximately ₹0.20 crore means Titan Biotech's improvement in operating performance translated efficiently into higher PBT and PAT.
Titan Biotech shares were locked near the 5% upper circuit in early trade on Friday, August 14, after the company reported strong Q1 FY27 performance. As per Business Standard, the stock was trading at ₹411.10, up 4.99% compared with the previous close of ₹391.55, with the stock's open, high and low all at ₹411.10 during the early session. The stock's 52-week high stands at ₹555.65, while its 52-week low is ₹88.04. The strong stock-market reaction appears to be driven by the combination of growth and margin expansion, with the company's earnings growing substantially faster than revenue - a 27% increase in revenue translated into 43% EBITDA growth, 57% PBT growth and a 58% jump in consolidated PAT. For investors, the next key monitor will be whether Titan Biotech can maintain EBITDA margins above 20% while continuing its current double-digit revenue growth trajectory.
